Clinical trials: Adnexal Tumor
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
This phase I trial investigates the side effects and best dose of abexinostat and palbociclib when given together with fulvestrant in treating patients with breast or gynecologic cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT04498520
- Testing
- Abexinostat Tosylate, Fulvestrant, Palbociclib
- Sponsor
- Pamela Munster
Ovarian Cancer
Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer
PARP inhibitors, such as olaparib, significantly improve progression free survival (PFS) in participants with recurrent, platinum-sensitive high-grade serous/endometrioid ovarian cancer (HGS/EOC), who harbour a germline mutation…
- Trial name
- MOLTO (NCT02855697)
- Testing
- Olaparib, Cediranib, Platinum-based Chemotherapy
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- The Christie NHS Foundation Trust
Cancer
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
RATIONALE: White blood cells that have been treated in the laboratory may kill cells that are infected with cytomegalovirus. PURPOSE: This phase I trial is studying how well cytotoxic T cells work in treating patients who have…
- Trial name
- NCT00769613
- Testing
- cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
Ovarian Cancer, Primary Peritoneal Cancer
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod
This research study is evaluating the effect (good and bad) of a dendritic cell/tumor fusion vaccine in combination with the laboratory made agents GM-CSF and imiquimod on the participants immune system.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT00799110
- Testing
- GM-CSF, Dendritic Cell/Tumor Fusion Vaccine, imiquimod
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Beth Israel Deaconess Medical Center
Ovarian Carcinoma
IGFBP-3 in Ovarian Cancer Invasion
An ovarian cancer cell line (OVTW-59) derived from an ovarian endometrioid carcinoma was established and its sublines, labeled as P0, P1, P2, P3, and P4 with increasing invasion abilities were selected from transwell invasion…
- Trial name
- NCT00154986
- Testing
- immunohistochemical staining, transfection, invasion assay
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Ovarian Cancer, Breast Cancer
A Study of Serum Folate Levels in Patients Treated With Olaparib
This is a study investigating folate deficiency (lack of folic acid in the blood) in patients who take the drug olaparib to treat their advanced ovarian or breast cancer.
- Conditions
- Ovarian Cancer, Breast Cancer, Folic Acid Deficiency
- Trial name
- NCT04024254
- Testing
- Folic Acid Tablet
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Rush University Medical Center
Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor
Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
This phase I trial is studying the side effects and best dose of polyglutamate paclitaxel when given together with carboplatin in treating patients with ovarian epithelial, peritoneal, or fallopian tube cancer.
- Conditions
- Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT00060359
- Testing
- Carboplatin, Paclitaxel Poliglumex, Pharmacological Study
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Fallopian Tube Carcinoma
SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
This study is an open-label, dose-escalation, investigator-initiated phase I interventional clinical study. To evaluate the safety, tolerability and preliminary efficacy of SCT-001 CAR-T cell injection in subjects with relapsed…
- Conditions
- Ovarian Cancer, Fallopian Tube Carcinoma, Peritoneal Carcinoma
- Trial name
- NCT06846424
- Testing
- SCT-001 CAR-T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Ovarian Cancer
Chemotherapy Supported by Autologous Hematopoietic Stem Cells
The aim of this project is to use autologous haematopoietic stem cell transfusion support to promote the reconstruction of haematopoietic function after chemotherapy for ovarian cancer.
- Trial name
- NCT05401162
- Testing
- Autologous blood transfusion with haematopoietic stem cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chongqing University Cancer Hospital
Ovarian Cancer
Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer
This project is a pilot, phase II, open-label, single-center, non-comparative clinical study evaluating the antitumor efficacy and tolerability of exemestane in treating adult post-menopausal women with recurrent or refractory…
- Trial name
- NCT00261027
- Testing
- Exemestane
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Hospital Research Institute
Cervix Cancer, Endometrial Cancer
Opioid Free Anaesthesia in Oncologic Gynaecological Surgery: Is There Any Benefit?
Opioid Free Anesthesia (OFA) is a multimodal anesthesia and emerging technique that spares the use of opioids and involve other adjuvant anesthetics, which have demonstrated in vitro influence on immunologic and inflammatory…
- Conditions
- Cervix Cancer, Endometrial Cancer, Ovarian Cancer, Breast Cancer
- Trial name
- NCT05448586
- Testing
- Opioid
- Where
- Spain
- Volunteers
- 132 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Polycystic Ovary Syndrome
The Study of Polycystic Ovary Syndrome(PCOS) With Gene and Questionnaire
Polycystic ovary syndrome (PCOS) is an extremely common disorder in women of reproductive age. Diagnosis of PCOS is principally based on clinical and physical findings.
- Trial name
- NCT01114659
- Where
- Taiwan
- Volunteers
- 169 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University WanFang Hospital
Ovarian Cancer
CanRisk-Based Ovarian Cancer Risk Assessment Versus Standard Practice (DISARM CSA)
The purpose of this study is to improve how the risk of developing ovarian cancer is assessed in people who may be at increased risk of ovarian cancer due to their family history or genetic background.
- Trial name
- DISARM CSA (NCT07809659)
- Testing
- CanRisk, Standard clinical risk assessment
- Where
- 6 sites in Czechia, Greece and 2 more
- Volunteers
- 2,130 people, healthy volunteers welcome
- Sponsor
- Instituto Portugues Oncologia de Lisboa Francisco Gentil
Polycystic Ovary Syndrome
The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists
Background: Brown adipose tissue (BAT) is a type of fat in the body. It may prevent weight gain, improve insulin sensitivity, and reduce fatty liver. Researchers want to see if BAT helps the body burn energy.
- Trial name
- NCT03049462
- Testing
- Mirabegron, B Complex Plus Vitamin C Tablets
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Solid Tumor, TNBC - Triple-Negative Breast Cancer
TH1902 in Patients With Advanced Solid Tumors
Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard…
- Conditions
- Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT04706962
- Testing
- TH1902
- Where
- 6 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Theratechnologies
Malignant Ovarian Clear Cell Tumor, Recurrent Ovarian Carcinoma
Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer
This phase II trial studies how well pembrolizumab and epacadostat work in treating patients with ovarian clear cell carcinoma that has come back (recurrent), remains despite treatment (persistent), or is growing, spreading, or…
- Trial name
- NCT03602586
- Testing
- Epacadostat, Pembrolizumab
- Where
- 363 sites in United States, Puerto Rico
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Fallopian Tube Cancer
Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer
This is a Phase 1 first in human, open label, multi-center, dose escalation study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-172154 in subjects with ovarian cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT04406623
- Testing
- SL-172154
- Where
- 6 sites in United States
- Volunteers
- 27 people
- Sponsor
- Shattuck Labs, Inc.
CLDN6-positive Solid Tumor, Ovarian Cancer
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Before a treatment can be approved for use, clinical studies need to be done. This study is for people with certain types of cancer that have become worse and are difficult to treat.
- Conditions
- CLDN6-positive Solid Tumor, Ovarian Cancer, Endometrial Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT06681870
- Testing
- ASP1893
- Sponsor
- Astellas Pharma Global Development, Inc.
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer
RATIONALE: Estrogen can stimulate the growth of ovarian cancer cells. Hormone therapy using arzoxifene hydrochloride may fight ovarian or peritoneal cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00003670
- Testing
- arzoxifene hydrochloride
- Where
- 4 sites in United States
- Sponsor
- Eli Lilly and Company
Ovarian Cancer, Endometrial Cancer
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study.
- Conditions
- Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor
- Trial name
- NCT06276491
- Testing
- XmAb541
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 282 people
- Sponsor
- Xencor, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.